ArticleeLife2019
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 126 citations in OpenAlex.
- Next-generation natural killer cell therapy: bench to bedside and beyond.Signal transduction and targeted therapy · 2026Review
- Article
- Review
- The dual roles of natural killer cells in liver immunity and tolerance: Implications for health and disease.Hepatology communications · 2026Review
- Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target.Infectious agents and cancer · 2026Review
- Acute peritonitis-induced adipose CD127Nature communications · 2026Article
- The shifting balance: innate lymphoid cell plasticity in chronic gut diseases.Frontiers in immunology · 2026Review
- Is there any association between latent Toxoplasma gondii seropositivity and hypothyroidism? A case-control registry-based study.BMC infectious diseases · 2025Article
- TGF-β drives the conversion of conventional NK cells into uterine tissue-resident NK cells to support murine pregnancy.bioRxiv : the preprint server for biology · 2025Article
- Review
- Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features.Nature communications · 2025Article
- De-coupling immune parameters and toxicity associated with IL-12 agonism.Cell reports · 2025Article
- Regulation of innate lymphoid cell by microbial metabolites.Journal of molecular medicine (Berlin, Germany) · 2025Review
- A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum.iScience · 2025Article
- Autocrine TGF-β1 drives tissue-specific differentiation and function of resident NK cells.The Journal of experimental medicine · 2025Article
- Natural killer cells in skin: a unique opportunity to better characterize the many facets of an overlooked secondary lymphoid organ.Frontiers in immunology · 2025Review
- Influence of MyD88 and αβ T cells on mesenteric lymph node innate lymphoid cell populations during Toxoplasma gondii infection.PloS one · 2025Article
- Article
- Tissue-specific features of innate lymphoid cells in antiviral defense.Cellular & molecular immunology · 2024Review
- Distinct developmental pathways generate functionally distinct populations of natural killer cells.Nature immunology · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
Abstract
Innate lymphoid cells (ILCs) were originally classified based on their cytokine profiles, placing natural killer (NK) cells and ILC1s together, but recent studies support their separation into different lineages at steady-state. However, tumors may induce NK cell conversion into ILC1-like cells that are limited to the tumor microenvironment and whether this conversion occurs beyond this environment remains unknown. Here, we describe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.